«Synthetic lethality represents a powerful, personalized approach to treating cancer, and IDEAYA is well positioned to advance the next wave of biomarker - driven
synthetic lethality therapies into the clinic,» said Thilo Schroeder, Ph.D., partner at Nextech Invest Ltd..
IDEAYA is pioneering the next generation of biomarker - enabled
synthetic lethality therapies for genetically defined patient populations and advancing an immuno - oncology pipeline targeting immuno - metabolism and innate immunity.
Not exact matches
IDEAYA Biosciences, Inc., an oncology - focused biotechnology company committed to the discovery of breakthrough
synthetic lethality medicines and immuno - oncology
therapies, announced today the successful completion of a $ 94 million crossover Series B financing.